Colorectal cancer screening
CRC screening · Gastroenterology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Population and risk-based screening detects early cancer and removes adenomas to reduce incidence and mortality. Faecal immunochemical testing (FIT) underpins population programmes, with colonoscopy for positive tests and higher-risk groups.
Red flags
- Rectal bleeding, change in bowel habit, weight loss, anaemia (urgent diagnostic referral, not screening)
- Positive FIT (needs colonoscopy)
- Strong family history / known hereditary syndrome
- Mass or stricture at colonoscopy
Assessment
Differential diagnosis
- Sporadic average-risk population
- Family history / Lynch syndrome / FAP (high-risk pathways)
- Inflammatory bowel disease surveillance (separate programme)
- Symptomatic patients (diagnostic, not screening, pathway)
Investigations
- Faecal immunochemical test (FIT) as primary screen
- Colonoscopy for FIT-positive and high-risk individuals
- CT colonography where colonoscopy incomplete/contraindicated
- Genetic testing/counselling for suspected hereditary syndromes
- Family history assessment to assign risk category
Management
- Identify the individual's risk category: average, increased (family history), or high (hereditary syndrome, IBD)
- Offer population FIT-based screening at the programme's defined age range and interval
- Refer FIT-positive individuals promptly for colonoscopy
- At colonoscopy, resect all adenomas and classify findings to set surveillance
- For significant family history, start colonoscopic screening earlier and at shorter intervals
- Enter confirmed Lynch syndrome into 2-yearly colonoscopy with earlier commencement
- Manage FAP with appropriate colonoscopic/flexible sigmoidoscopy surveillance and surgical planning
- Counsel high-risk patients and refer for genetic testing where indicated
- Use CT colonography if colonoscopy is incomplete or unsuitable
- Ensure symptomatic patients enter the urgent diagnostic (not screening) pathway
- Reinforce modifiable risk reduction (smoking, alcohol, diet, activity, weight)
Drugs & doses
Aspirin — considered for chemoprevention in Lynch syndrome (specialist decision)
Bowel preparation agents for colonoscopy (e.g. macrogol-based)
Disposition
Population screening programme; high-risk and hereditary cases to genetics and specialist surveillance.
Complications & pitfalls
- Interval cancers (missed/declined screening)
- Colonoscopy risks: bleeding, perforation
- Over-surveillance harms and resource burden
- Anxiety/false positives
Exam pearls
- Symptomatic patients need the urgent diagnostic pathway — screening is for asymptomatic individuals
- FIT is central to modern population screening and triages who needs colonoscopy
- Lynch syndrome warrants earlier, 2-yearly colonoscopy and consideration of aspirin chemoprevention
- Adenoma removal at colonoscopy is what prevents cancer, not just detection
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.